Drilldown: Medicines
Use the filters below to narrow your results.
generic: (Click arrow to add another value)
brand:
classes:
Anti-CGRP ligand monoclonal antibody (2) ·
Anti-CGRP receptor monoclonal antibody (1) ·
[[:Category:Biologics|Biologic]] (1) ·
[[:Category:DMARDs|DMARD]] (1) ·
[[:Category:Immunosuppressants|Immunosuppressant]] (1) ·
[[:Category:Monoclonal_antibodies|Monoclonal antibody (fully human IgG1)]] (1) ·
[[:Category:TNF_inhibitors|TNF-α inhibitor]] (1)
mechanism:
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) ·
Humanized IgG2 monoclonal antibody binding the CGRP receptor (not the peptide); blocks CGRP-mediated vasodilation and nociceptive signaling (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
'"`UNIQ--vote-000010F8-QINU`"' Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response'"`UNIQ--ref-000010F9-QINU`"'. (1)
uses:
starting dose:
225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) ·
40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week (1) ·
70 mg SC monthly; may increase to 140 mg monthly (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)
preparations:
fda max:
routes: (Click arrow to add another value)
onset:
bioavailability:
pregnancy:
Showing below up to 4 results in range #1 to #4.